<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856098</url>
  </required_header>
  <id_info>
    <org_study_id>3131001</org_study_id>
    <nct_id>NCT04856098</nct_id>
  </id_info>
  <brief_title>Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler</brief_title>
  <acronym>FINDA</acronym>
  <official_title>A Pharmacokinetic Feasibility Study on Ultibro Breezhaler, an Indacaterol-glycopyrronium Inhalation Powder Capsule, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess pharmacokinetics (PK) of indacaterol and&#xD;
      glycopyrronium, and methodology and practical arrangements for future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Actual">September 21, 2021</completion_date>
  <primary_completion_date type="Actual">September 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is a 2-part crossover study where the study subjects participate either in part 1 (18 subjects) or in part 2 (16 subjects). The parts can run in sequence or in parallel. The study subjects in part 1 receive single doses of Ultibro Breezhaler on 3 periods and the study subjects in part 2 receive single doses of Ultibro Breezhaler on 2 periods.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak indacaterol concentration in plasma (Cmax)</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak glycopyrronium concentration in plasma (Cmax)</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Indacaterol area under the concentration-time curve from time zero to 30 minutes (AUC30min)</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycopyrronium area under the concentration-time curve from time zero to 30 minutes (AUC30min)</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Indacaterol area under the concentration-time curve from time zero to 72 hours (AUC72h)</measure>
    <time_frame>0-72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycopyrronium area under the concentration-time curve from time zero to 72 hours (AUC72h)</measure>
    <time_frame>0-72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indacaterol area under the concentration-time curve from time zero to the last sample with a quantifiable concentration (AUCt)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycopyrronium area under the concentration-time curve from time zero to the last sample with a quantifiable concentration (AUCt)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indacaterol area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycopyrronium area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak indacaterol concentration in plasma</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak glycopyrronium concentration in plasma</measure>
    <time_frame>between 0-72 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indacaterol terminal elimination half-life (t1/2)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycopyrronium terminal elimination half-life (t1/2)</measure>
    <time_frame>0-18 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events as event counts and subjects counts</measure>
    <time_frame>throughout the study, average 9-12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1 Ultibro Breezhaler 2 capsules, Batch A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Ultibro Breezhaler 1 capsule, Batch A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Ultibro Breezhaler 2 capsules, Batch A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Ultibro Breezhaler 2 capsules, Batch B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol maleate and glycopyrronium bromide</intervention_name>
    <description>Batch A Ultibro Breezhaler 85/43 μg 2 capsules</description>
    <arm_group_label>Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A</arm_group_label>
    <arm_group_label>Part 1 Ultibro Breezhaler 2 capsules, Batch A</arm_group_label>
    <arm_group_label>Part 2 Ultibro Breezhaler 2 capsules, Batch A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol maleate and glycopyrronium bromide</intervention_name>
    <description>Batch A Ultibro Breezhaler 85/43 μg 1 capsule</description>
    <arm_group_label>Part 1 Ultibro Breezhaler 1 capsule, Batch A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol maleate and glycopyrronium bromide</intervention_name>
    <description>Batch B Ultibro Breezhaler 85/43 μg 2 capsules</description>
    <arm_group_label>Part 2 Ultibro Breezhaler 2 capsules, Batch B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultibro Breezhaler with oral charcoal</intervention_name>
    <description>Activated charcoal suspension, granules 50 g / bottle</description>
    <arm_group_label>Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:&#xD;
&#xD;
          1. Healthy males and females&#xD;
&#xD;
          2. 18-60 years of age&#xD;
&#xD;
          3. Body mass index 19-30 kg/m2&#xD;
&#xD;
          4. Weight at least 50 kg&#xD;
&#xD;
          5. Written informed consent obtained&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             GI, pulmonary, metabolic, endocrine, neurological or psychiatric disease&#xD;
&#xD;
          2. Any condition requiring regular concomitant treatment&#xD;
&#xD;
          3. Any clinically significant abnormal laboratory value, vital sign or physical finding&#xD;
             that in the opinion of the investigator could interfere with the interpretation of&#xD;
             study results or cause a health risk for the subject&#xD;
&#xD;
          4. Known hypersensitivity to indacaterol or glycopyrronium&#xD;
&#xD;
          5. Pregnant or lactating females and females of childbearing potential not using&#xD;
             contraception of acceptable effectiveness&#xD;
&#xD;
          6. Blood donation or loss of significant amount of blood within 90 days prior to the&#xD;
             first study treatment administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Corporation Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRST Helsinki Oy</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

